LW-231, under development by Shanghai Longwood Biopharmaceuticals Co. Ltd., is a novel bifunctional molecule designed to simultaneously modulate hepatitis B virus (HBV) capsid assembly and activate cGAS-STING pathway. Preclinical data were recently presented.
Researchers from Lerna Biopharma Pte. Ltd. (formerly Cargene Therapeutics Pte. Ltd.) recently presented the discovery and preclinical evaluation of a first-in-class GalNAc-siRNA therapeutic, CG-LR1, being developed for the treatment of liver diseases.
Researchers from Ipsen Ltd. and affiliated organizations presented the discovery and preclinical characterization of a novel NTCP inhibitor, A-7387, being developed for the treatment of HBV and HDV infections.
Omega Therapeutics Inc. has presented preclinical data on hepatocyte nuclear factor 4-alpha (HNF4A) modulation in fibrotic liver disease models to enhance its key role and suggest it as a potent therapeutic target.
Researchers from Aligos Therapeutics Inc. presented preclinical data for ALG-001075, a novel capsid assembly modulator leading to the formation of empty capsids (CAM-E), being developed for the treatment of hepatitis B.
Researchers from Aligos Therapeutics Inc. have presented the discovery and preclinical evaluation of a novel next-generation liver targeted PD-L1 small molecule inhibitor, ALG-094103, which is being developed for the treatment of chronic hepatitis B and liver cancer.
It’s known that interferon-alpha (IFNα) activates interferon-stimulated genes (ISGs) and disrupts the hepatitis B virus (HBV) replication cycle. Pegylated (PEG)-IFNα has been widely used for its immunomodulatory and antiviral properties but it is not always well tolerated and thus its use is limited.